Just over a month ago, we completed an exciting and important acquisition of the remaining equity in our drug discovery holding, ReceptoPharm.  Even though it has taken more than a year and a half since we first signed a letter of intent to acquire them, we are just as excited today as we were in June 2006 about the opportunity to work with such a talented group of scientists to develop innovative drugs and bring them through the FDA approval process.

Before the acquisition, we had already developed a close relationship with the team at ReceptoPharm. We owned just over 38% of the Company and it acted as our drug discovery holding. Now that the acquisition is officially complete, we are going to be working even more closely to provide them with the resources they will need to initiate and complete human clinical trials for several indications.

Our number one goal here at Nutra Pharma is to develop innovative treatments for some of the most pernicious medical disorders. Since our first opportunity to work with ReceptoPharm, we have felt that the goals of our two companies closely aligned. It is for this reason that our acquisition was just a natural progression of our relationship over the past several years.

Currently we are conducting a Phase IIb/IIIa trial for the treatment of Adrenomyeloneuropathy, a disease for which there is no current treatment. This trial is scheduled to be completed this summer.

Now that ReceptoPharm is a part of the Nutra Pharma family, we will be focusing even more on our efforts to bring treatments through the FDA approval process. In the short-term, we are planning to initiate Phase II clinical trials for the treatment of HIV and Multiple Sclerosis and begin trials for Feline Leukemia Virus. As we continue, we plan on expanding our development to include additional trials for Herpes, pain, Rabies, and Rheumatoid Arthritis.

While it is never clear what obstacles we will face in the future, there is one thing we do know for certain; by combining forces with ReceptoPharm we are now better prepared than ever to successfully achieve our drug development goals.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " A further explanation about our acquisition of ReceptoPharm", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

Comments

No comments yet.

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website